Abstract
We thank Dr Coscas and colleagues for their interest in our recent paper documenting a substantially higher risk of major amputation following use of paclitaxel coated balloons in the infra-inguinal arteries.1 The authors discuss the fact that the control arm in the PACUS trial had also received liquid paclitaxel at the treatment site. We would like to clarify that this has been noted and accounted for in our meta-analysis. First, as explained in the legend of Table 1, in the PACUS trial, DCB were randomised vs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Vascular and Endovascular Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
